Concepedia

Tao Meng

TM

Statistics

Publications

5

Citations

141

H-Index

5

Active since

2023

Affiliations

Guangdong Pharmaceutical University(Current)

Forma Therapeutics (United States)

Regend Therapeutics (China)

Sun Yat-sen University

Northwest University

Tao Meng is an author at Guangdong Pharmaceutical University specializing in oncology, targeted therapy, and antibody-drug conjugate therapy.

ORCID

Publications per year

2023–2025

5

Publications

5

Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer

Weining Weng, Tao Meng, Qianqian Zhao et al. · Cancer Discovery · 2023 · 76 citations

, , +17

AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Weining Weng, Tao Meng, Junyi Pu et al. · Molecular Cancer Therapeutics · 2023 · 26 citations · Full text

, , +17

A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma

Jing Shi, Tao Jiao, Qian Guo et al. · Cancer Research · 2023 · 15 citations · Full text

, , +16

MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors

Chao Kong, Junyi Pu, Qianqian Zhao et al. · Molecular Cancer Therapeutics · 2023 · 14 citations · Full text

, , +17

Construction of human pluripotent stem cell-derived testicular organoids and their use as humanized testis models for evaluating the effects of semaglutide

Rufei Huang, Huan Xia, Tao Meng et al. · Theranostics · 2025 · 10 citations · Full text

, , +15

1–5 of 5